glaucoma and semaglutide GLP-1 Meds Reduce Risk of Various Ocular Complications in Non-diabetic Patients Anterior ischemic optic neuropathy in

6.2 Novo Nordisk + Septerna (May 2025, up to $2.2B) Novo's second major triple-agonist transaction was a broader small-molecule GPCR collaboration with Septerna announced May 2025: up to $2.2 billion total deal value, $200 million+ upfront, covering four oral small-molecule GPCR programs

If youre concerned about these changes, its also a good idea to ask your healthcare provider to assess your risk for nutritional deficiencies

This positions LeoLab RX as the strongest overall transparency-focused vendor in this muscle growth peptide comparison

Dose comparison table Notice that retatrutide doses are measured in milligrams, similar to tirzepatide, but the dose range is different

CI=confidence interval